Inhalation drug delivery

We’re the pioneers in novel inhalation technologies. Our past achievements help lay a strong foundation for our partners’ programs, with a track record of industry firsts, from the first metered-dose inhaler (MDI) to developing tomorrow’s smart, connected inhalers.

˅
˄

Analytical & technical leadership

More than 60 years of industry-leading expertise in inhalation science and product development drives our success. We have the R&D expertise to go from molecule to patent. We have successfully developed and commercialized both mono and combination therapies and both generic and branded products.

  • Lab-scale and commercial experience formulating stable products
  • Formulations ranging from small molecules to macromolecules
  • Particle engineering & raw material screening
  • Phase appropriate method development & validation
  • Globally minded regulatory and clinical leadership
  • Expert data analysis and interpretation to support regulatory submissions
˅
˄

Innovative devices

Supported by an expansive portfolio of device IP, we’ve led the field. Bolstered by predictive engineering and rapid prototyping capabilities, we strive to be on the cutting edge of novel inhalation device development.

Inhalation device development

  • Metered-Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Digital/Connected Devices
  • Nasal MDIs
  • Components: Cannisters, Valves, Dose Counters
  • Application of Novel Coatings
˅
˄

Operational excellence

Our cGMP manufacturing sites are positioned to supply to global markets. Operating under strict quality standards, we are always audit-ready.

  • Automated filling and packaging lines
  • Cold-fill and pressure-fill capabilities
  • Micronization and powder handling technologies
  • Small-to-large order packaging flexibility

Microstructured Transdermal Systems (MTS)

Kindeva’s MTS platform provides elegant microneedle-based delivery devices, refined and suited to our partners’ programs.

˅
˄

Analytical & technical leadership

From early-phase feasibility to final design requirements, we can meet the needs of challenging drug formulations.

  • Feasibility and early-phase development capabilities
  • Human tolerability and human factors studies
  • Proven ability to develop challenging drug formulations
  • Preclinical and clinical capabilities
  • Regulatory leadership and expert data analysis to support submissions and filings
˅
˄

Innovative devices

Refined over several device generations, Kindeva’s microstructured systems are designed for consistent intradermal delivery of vaccines and biologics. Our patient-friendly technology is available in two formats, providing an option of delivery routes to enable your commercial success.

  • Solid Microneedles – offers potential for increased immunogenicity, dose sparing, cold chain elimination, and increased patient convenience via self-administration
  • Hollow Microneedles – offers reproducible intradermal delivery of a wide range of viscosities

 

˅
˄

Operational excellence

With sophisticated project management, rigorous quality processes, manufacturing excellence, and cGMP facilities, Kindeva supports a reliable supply chain for your program.

  • Automated Array Molding and Packaging
  • Aseptic Array Coating for Solid Microneedles
  • Qualified Equipment for Device Assembly Process
  • Manufacturing capability for Preclinical, Clinical, and Scale-up Activities
Transdermal drug formulation

Transdermal drug delivery

Our half-century history of integrating adhesive, drug, and components into a single product shows we understand transdermal patches, start to finish.

˅
˄

Analytical & technical leadership

A half-century of transdermal experience equals a winning record of technical, regulatory, and commercial success. We have the capability of developing both mono and combination therapies and have successfully launched both generic and branded transdermal products.

  • Feasibility and early phase development
  • Lab-scale and commercial experience developing transdermal formulations
  • Integration of adhesive, drug, and components
  • Adhesive and polymer science expertise
  • Application expertise
  • Globally minded regulatory and clinical leadership
˅
˄

Innovative devices

Our knowledge and expertise has resulted in new ways to work with transdermal science.

  • Single-layer drug-in-adhesive patches
  • Multi-layer drug-in-adhesive patches
  • Gel patches
  • Customizable patch design and geometries
˅
˄

Operational excellence

With modern transdermal manufacturing capabilities, we supply our partners with small to commercial volumes reliably and efficiently. Our audit-ready facilities maintain robust quality management processes in cGMP conditions.

  • Automated coating lines
  • High efficiency converting technology
  • Packaging and carton capabilities
  • Finished and intermediate product configurations
  • Handling of controlled substances

A history of launching next-generation drug delivery systems

Learn more